Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1228 ARTÍCULOS , VIENDO DEL 886 AL 900

Reference measurement procedure for CSF amyloid beta (Aβ)(1-42) and the CSF Aβ(1-42) /Aβ(1-40) ratio - a cross-validation study against amyloid PET

Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, Hansson O, Blennow K.

J Neurochem. 2016 Nov;139(4):651-658. doi: 10.1111/jnc.13838. Epub 2016 Sep 30.

Genetic Association of CHAT rs3810950 and rs2177369 Polymorphisms with the Risk of Alzheimer's Disease: A Meta-Analysis

Liu Y, Chen Q, Liu X, Dou M, Li S, Zhou J, Liu H, Wu Y, Huang Z.

Biomed Res Int. 2016;2016:9418163. doi: 10.1155/2016/9418163. Epub 2016 Aug 15.

Detecting Alzheimer's disease biomarkers: From antibodies to new bio-mimetic receptors and their application to established and emerging bioanalytical platforms - A critical review

Scarano S, Lisi S, Ravelet C, Peyrin E, Minunni M.

Anal Chim Acta. 2016 Oct 12;940:21-37. doi: 10.1016/j.aca.2016.08.008. Epub 2016 Aug 10.

Searching biomarkers for mental disorders-lessons from Alzheimer's disease

Maier W.

Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7):583-5. doi: 10.1007/s00406-016-0732-3.

[Clinical Implications and Appropriate Use of Amyloid Imaging with florbetapir ((18)F) in Diagnosis of Patients with Alzheimer Disease]

Nakamura T, Iwata A, Ueda K, Namiki C.

Brain Nerve. 2016 Oct;68(10):1215-1222. doi: 10.11477/mf.1416200578.

Expression of Alzheimer's disease risk genes in ischemic brain degeneration

Ułamek-Kozioł M, Pluta R, Januszewski S, Kocki J, Bogucka-Kocka A, Czuczwar SJ.

Pharmacol Rep. 2016 Dec;68(6):1345-1349. doi: 10.1016/j.pharep.2016.09.006. Epub 2016 Sep 5.

Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years

McGeer PL, Rogers J, McGeer EG.

J Alzheimers Dis. 2016 Oct 4;54(3):853-857. doi: 10.3233/JAD-160488.

Alzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics

Hickman RA, Faustin A, Wisniewski T.

Neurol Clin. 2016 Nov;34(4):941-953. doi: 10.1016/j.ncl.2016.06.009. Epub 2016 Aug 4.

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease

Brody M, Liu E, Di J, Lu M, Margolin RA, Werth JL, Booth K, Shadman A, Brashear HR, Novak G.

J Alzheimers Dis. 2016 Oct 18;54(4):1509-1519. doi: 10.3233/JAD-160369.

Alzheimer disease: Biomarkers of AD risk - the end of the road for plasma amyloid-β?

Wood H.

Nat Rev Neurol. 2016 Nov;12(11):613. doi: 10.1038/nrneurol.2016.160. Epub 2016 Oct 14.

Towards Personalized Intervention for Alzheimer's Disease

Peng X, Xing P, Li X, Qian Y, Song F, Bai Z, Han G, Lei H.

Genomics Proteomics Bioinformatics. 2016 Oct;14(5):289-297. doi: 10.1016/j.gpb.2016.01.006. Epub 2016 Sep 28.

Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies

Golde TE.

J Neurochem. 2016 Oct;139 Suppl 2(Suppl 2):224-236. doi: 10.1111/jnc.13583. Epub 2016 May 4.

Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease

Kulic L, Unschuld PG.

Curr Opin Neurol. 2016 Dec;29(6):749-755. doi: 10.1097/WCO.0000000000000399.

Advances in Aβ plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease

Jovalekic A, Bullich S, Catafau A, de Santi S.

Neurodegener Dis Manag. 2016 Dec;6(6):491-497. doi: 10.2217/nmt-2016-0026. Epub 2016 Nov 4.

Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease

Ruthirakuhan M, Herrmann N, Suridjan I, Abraham EH, Farber I, Lanctôt KL.

Expert Opin Pharmacother. 2016 Dec;17(18):2417-2429. doi: 10.1080/14656566.2016.1258060. Epub 2016 Nov 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias